Top 5 Rising Companies To Own For 2014

It's official. Investors have begun to fear that interest rates will soon rise. Bond prices have increased and we've witnessed a sell-off of stocks. Is the party over for dividend-paying stocks?

Time to sweep up the confetti?
When interest rates are high, conservative investors can buy relatively safe securities, like government bonds, and live off the income they produce. When rates are low, as they've been during the past several years, the income investors receive drops sharply, making dividend-paying stocks much more attractive. So, with the recent belief that the U.S. economy is strengthening, should investors flee dividend-paying stocks?

In a word: no. The rise in rates won't happen overnight, and rates will need to rise significantly before dividend yields on stocks become unattractive. Right now, the average dividend yield of S&P 500 stocks stands at 2%, twice the yield of a five-year Treasury.

But the real power of dividend-paying stocks is that bonds simply cannot compete when it comes to generating rising income, an essential component of a retiree's portfolio. That's what allows you to pay for gas and groceries a decade from now. Good, quality companies keep increasing their dividends. Rising dividends on top of high yields is an unbeatable combination.

Top 5 Warren Buffett Stocks For 2015: Regus plc (RGV)

Regus plc is a Luxembourg-based provider of global office outsourcing services. Its primary activity and business segment is the provision of global workplace solutions. There are three parts to the Company�� business: Mature, New and Third Place. The Company�� products and services include outsourcing, workplace recovery, business lounges, businessworld, meeting rooms, video communications, offices and virtual offices. It offers bespoke packages for starting a business, home based business, mall and medium business, international business and corporate workspace solutions. It has some 1,203 locations across 550 cities in 94 countries serving more than a million customers. Its principal geographical segments include Americas; Europe, Middle East and Africa; Asia Pacific; and the United Kingdom. In June 2013, Regus plc announced that it has launched its business centre in Nepal. Advisors' Opinion:

• [By Holly LaFon]

  Whitney George is Director of Investments, Managing Director, and a Portfolio Manager of Royce & Associates, LLC, investment advisor to The Royce Funds. He serves as portfolio manager for Royce Premier Fund (RPR), Royce Low-Priced Stock Fund (RLP), Royce Global Value Fund (RGV), Royce SMid-Cap Value Fund (RSV), and Royce Focus Trust (FUND). He also serves as assistant portfolio manager for Royce Micro-Cap Fund (RMC), Royce Value Fund (RVV), Royce Value Plus Fund (RVP), Royce Focus Value Fund (RFV), and Royce Capital Fund ��Micro-Cap Portfolio (RCM). Mr. George's thoughts in this interview concerning the stock market are solely his own and, of course, there can be no assurance with regard to future market movements.

Top 5 Rising Companies To Own For 2014: Dun & Bradstreet Corp (DNB)

The Dun & Bradstreet Corporation (D&B), incorporated on April 25, 2000, is the source of commercial information and insight on businesses, enabling customers to Decide with Confidence. As of December 31, 2012, the Company�� global commercial database contained more than 220 million business records. The database is enhanced by its DUNSRight Quality Process, which transforms commercial data into valuable insight which is the foundation of its global solutions. Customers use D&B Risk Management Solutions to mitigate credit and supplier risk, increase cash flow and drive profitability; D&B Sales & Marketing Solutions to provide data management capabilities that provide marketing solutions to increase revenue from new and existing customers, and D&B Internet Solutions to convert prospects into clients by enabling business professionals to research companies, executives and industries.

The Company operates in three segments: North America (which consists of its operations in the United States and Canada); Asia Pacific (which primarily consists of its operations in Australia, Greater China, India and Asia Pacific Worldwide Network), and Europe and other International Markets (which primarily consists of its operations in the United Kingdom, the Netherlands, Belgium, Latin America and its European Worldwide Network). The Company conducts its business internationally through its wholly owned subsidiaries, majority-owned joint ventures, independent correspondents, strategic relationships through its D&B Worldwide Network and minority equity investments.

Risk Management Solutions

The Company provides traditional, value-added and supply management solutions. The Company�� Traditional Risk Management Solutions, which primarily includes its core DNBi product line, as well as reports from its database which are used primarily for making decisions about new credit applications, constituted 74% of its Risk Management Solutions revenue and 47% of its total revenue for the ye! ar ended December 31, 2012. Its Value-Added Risk Management Solutions, which constituted 20% of its Risk Management Solutions revenue and 12% of its total revenue for the year ended December 31, 2012, generally support automated decision-making and portfolio management through the use of scoring and integrated software solutions. The Company�� Supply Management Solutions, which can help companies understand the financial risk of their supply chain, constituted 6% of its Risk Management Solutions revenue and 4% of its total revenue in 2012. Risk Management Solutions accounted for 63% of its total revenue in 2012.

Effective January 1, 2013, the Company began managing and reporting its North America Risk Management Solutions business as DNBi subscription plans, Non-DNBi subscription plans, and projects and other risk management solutions.

The Company�� principal Risk Management Solutions are DNBi, various business information reports, eRAM, and D&B Direct. DNBi is the Company�� interactive, customizable online application that offers customers a subscription based real time access to its complete and up-to-date global DUNSRight information, comprehensive monitoring and portfolio analysis. It is also focused on helping more customers protect their business from risk through additions of DNBi products: DNBi Corporate, offering flexible pricing options allowing credit departments of all sizes to get data and options they need and Portfolio Risk Manager for DNBi, a module which allows DNBi users to create strategic one -click analytic reports to see risk and opportunity across their customer base. Various business information reports include Business Information Report, its Comprehensive Report, and its International Report that are consumed in a transactional manner across multiple platforms, such as DNB.com. eRAM is an enterprise solution for large global and domestic customers for automated decisioning and portfolio analytics. D&B Direct is a software application programming inter! face (API! ) that enables data integration inside enterprise applications, such as ERP, and enables master data management.

Sales & Marketing Solutions

The Company�� Sales & Marketing Solutions is a customer solution set, which accounted 29% of its total revenue in 2012. Within this customer solution set, it offers traditional and value-added solutions. Its Traditional Sales & Marketing Solutions generally consist of its marketing lists and labels used by the Company�� customers in direct mail and marketing activities, its education business and its electronic licensing solutions. These solutions constituted 30% of its Sales & Marketing Solutions revenue and 9% of its total revenue in 2012. Effective January 1, 2013, The Company began managing and reporting its Internet Solutions business as part of its Traditional Sales & Marketing Solutions set. Its Value-Added Sales & Marketing Solutions generally include decision-making and customer information management solutions, including data management solutions like Optimizer (its solution to cleanse, identify and enrich its customers' client portfolios) and products introduced as part of its Data-as-a-Service (DaaS) Strategy, which integrates the Company�� data directly into the applications and platforms that its customers use every day. The Value-Added Sales & Marketing Solutions constituted 70% of Sales & Marketing Solutions revenue and 20% of its total revenue in 2012

Internet Solutions

The Company�� Internet Solutions business provides organized and easy-to-use products that address the online sales and marketing needs of professionals and businesses, including information on companies, industries and executives. Internet Solutions, primarily representing the results of its Hoover's business, accounted for 7% of its total revenue in 2012. Effective January 1, 2013, the Company began managing and reporting its Internet Solutions business as part of its Traditional Sales & Marketing Solutions set.

T! he Company competes with Equifax, Inc., Experian Information Solutions, Inc., infoGROUP, Graydon, and Sinotrust.

Advisors' Opinion:

• [By Geoff Gannon] street costs $80.27 a share. So $100 will buy you 1.25 shares of Dun & Bradstreet. Dun & Bradstreet has $5.29 in earnings per share. So, 1.25 shares would deliver $6.61 a share in earnings. We can think of $6.61 a share in earnings as the amount of present earnings your $100 can buy you in Dun & Bradstreet stock.

  Coach grew revenue per share 20% over the last five years. While Dun & Bradstreet grew revenue per share 9% a year over the last five years.

  Let�� imagine ��just for the sake of argument ��what would happen if Dun & Bradstreet and Coach both grew their earnings for the next five years at the same pace they grew them over the last five years.

  This is how much earnings my same $100 would buy in each stock:

  Coach (COH) Dun & Bradstreet (DNB) Today $4.39 $6.61 2012 $5.27 $7.20 2013 $6.32 $7.85 2014 $7.59 $8.56 2015 $9.11 $9.33 2016 $10.93 $10.17

  In four years, my $100 investment in Coach would be earning nearly the same amount per year as my $100 investment in Dun & Bradstreet. And in five years, Coach�� earnings would pass Dun & Bradstreet�� earnings.

  If Coach�� growth prospects still looked good in five years, the stock might have a P/E of 20. Meanwhile, Dun & Bradstreet�� growth might still be barely inching along. Actual sales growth at DNB is only around 3% a year. The per share growth is due to constant share buybacks. Check out Dun & Bradstreet�� 10-year financial summary for evidence of the mammoth stock buyback they��e done over the last decade. Shares outstanding have declined almost 40%.

  Anyway, if DNB�� organic sales growth was around 3% or so five years from now ��the stock could easily have a P/E of 12. So, you could certainly imagine a scenario five years from now where Coach�� price per share is $219 ($10.93 * 20) while Dun & Bradstreet�� stock price is only $122 ($10.17 * 12).

  I can�� argue with that. It�� certainly possible. Personally, I�� not at all sure a P/

Top 5 Rising Companies To Own For 2014: Fox Chase Bancorp Inc. (FXCB)

Fox Chase Bancorp, Inc. operates as the holding company for Fox Chase Bank that provides financial services to consumers and businesses in Philadelphia and New Jersey. Its deposit products include non-interest-bearing demand accounts, such as checking accounts; interest-bearing accounts, including negotiable order of withdrawal and money market accounts; savings and club accounts; brokered deposits; and certificates of deposit. The company�s loan products portfolio comprises multi-family and commercial real estate loans; one-to four-family residential real estate loans that enable borrowers to purchase or refinance existing homes; commercial and industrial loans offered to professionals, sole proprietorships, and small and mid-size businesses; construction loans comprising adjustable-rate and fixed-rate loans offered to individuals, builders, and developers to finance the construction of residential dwellings, as well as loans offered for commercial development projects, including apartment buildings, restaurants, shopping centers, schools, and other owner-occupied properties used for businesses; and consumer loans, which include home equity loans and lines of credit, loans to individuals to purchase insurance policies, loans secured by certificate of deposits, and unsecured overdraft lines of credit. It also offers cash management services. In addition, the company manages and holds investment securities; and secures, manages, and holds foreclosed real estate. It operates through 11 branches in Philadelphia, Richboro, Willow Grove, Warminster, Lahaska, Hatboro, Media, and West Chester, Pennsylvania; and Ocean City, Marmora, and Egg Harbor Township, New Jersey. The company is headquartered in Hatboro, Pennsylvania.

Advisors' Opinion:

• [By Tim Melvin]

  To start, Seidman disclosed a position in Fox Chase Bancorp (FXCB), located in Hatboro, Pa. The bank is trading right around book value and has been a holding of mine for some time now. Me. Seidman owns a little over 5% of the bank.

Top 5 Rising Companies To Own For 2014: OncoMed Pharmaceuticals Inc (OMED)

OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company's anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.

Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.

Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.

The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-bas! ed therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.

Advisors' Opinion:

• [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]

  The U.S. Food and Drug Administration on Wednesday imposed a partial clinical hold on a second cancer treatment trial by OncoMed Pharmaceuticals Inc.(OMED) The FDA’s action follows a similar hold last Friday on another treatment targeting cancer stem cells.

• [By WWW.DAILYFINANCE.COM]
  Stocks ended a mini-losing streak on Friday, led by upbeat news from Intel (INTC). The Dow Jones industrial average (^DJI) rose 41 points, after sliding more than 200 over the previous two days. The Nasdaq composite (^IXIC) gained 13 and the Standard & Poor's 500 index (^GPSC) added 6 points. Those modest gains did little to trim the loss for the week. The major averages posted their biggest weekly declines in more than two months. Intel is a component of all three big indexes, and it jumped 7 percent after raising its revenue guidance for the current quarter. The company sees stronger business demand for PCs than it previously expected. Intel shares are up 23 percent over the past six months. The Intel news had a ripple effect. Computer maker Hewlett-Packard (HPQ) rose more than 5 percent and Microsoft (MSFT) gained 1½ percent. Part of the increased demand Intel points to is tied to corporate buyers who need to replace their Windows XP machines, because Microsoft has stopped providing technical support for that platform. But Apple (AAPL) lost more than 1 percent. The stock is down since its 7-for-1 stock split took effect on Monday. There were two other big stories that had some legs beyond the companies directly involved. Open Table (OPEN) agreed to be acquired by Priceline (PCLN) for $2.6 billion. Open Table, which provides restaurant reservations, jumped 48 percent. Other online service providers rode the coattails of that deal. Yelp (YELP) gained 14 percent and Groupon (GRPN) gained 4 percent. In the retail arena, Express (EXPR) jumped 21 percent after a private equity firm took a 9.9 percent stake in the teen retailer and indicated it may make a buyout offer. That gave a boost to Aeropostale (ARO) and American Eagle (AEO), which both rose more than 2 percent. Abercrombie & Fitch (ANF) gained 1½. Elsewhere, International Game Technology (IGT) gained 10½ percent on a Reuters report that a bidding war could erupt for
• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)

• [By Jake L'Ecuyer]

  Equities Trading UP
  OncoMed Pharmaceuticals (NASDAQ: OMED) shot up 8.62 percent to $30.09 after the company initiated Phase 1B trial of WNT-parthway-target antibody. Jefferies lifted the price target on the stock from $27 to $46.